Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert
This article was originally published in The Tan Sheet
Executive Summary
FDA should allow researchers more flexibility to evaluate consumers’ purchase decisions in self-selection studies for OTC drugs, according to contract research organization PEGUS Research.
You may also be interested in...
Statin Label Change Stirs OTC Switch Discussions
FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.
Statin Label Change Stirs OTC Switch Discussions
FDA eliminates the label statement that liver function tests should be performed prior to and at 12 weeks following therapy or dose elevation, and periodically thereafter. A study design expert predicts better chances for a statin switch, but a consumer health advocate doubts nonprescription access will be safe.
Merck Mines Mevacor Switch Data To Press FDA On Self-Selection Stance
Purchase decisions in OTC switch self-selection studies offer insight into subjects’ thinking “and how they might act in a real-world pharmacy setting,” Merck tells FDA in response to a draft guidance that says such decisions are driven by cost and are “an unreliable surrogate” for self-selection.